PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 21, Issue 3, 2010, Pages 927-938

  Saresella, Marina ^a   Calabrese, Elena ^a   Marventano, Ivana ^a   Piancone, Federica ^a   Gatti, Andrea ^a   Calvo, Maria Gaetana ^a   Nemni, Raffaello ^a   Clerici, Mario ^a,b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; immunology; mild cognitive impairment; PD1; T regulatory cells

Indexed keywords

AMYLOID BETA PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

AGED; ALZHEIMER DISEASE; ARTICLE; CD4+ T LYMPHOCYTE; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 77957283905     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091696     Document Type: Article

References (59)

1. McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27, 741749.
2. Singh VK, Guthikonda P (1997) Circulating cytokines in Alzheimer's disease. J Psychiatr Res 31, 657660. (Pubitemid 27522448)
3. Solerte SB, Cravello L, Ferrari E, Fioravanti M (2000) Overproduction of IFN gamma and TNF fromnatural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann N Y Acad Sci 917, 331340.
4. Remarque EJ, Bollen EL, WeverlingRijnsburger AW, Laterveer JC, Blauw GJ, Westendorp RG (2001) Patients with Alzheimer's disease display a proinflammatory phenotype. Exp Gerontol 36, 171176. (Pubitemid 32012574)
5. Castle SC, Uyemura K, CrawfordW,WongW, Klaustermeyer WB, Makinodan T (1999) Agerelated impaired proliferation of peripheral blood mononuclear cells is associated with an increase in both IL10 and IL12. Exp Gerontol 34, 243252. (Pubitemid 29153021)
6. Lio D, Scola L, Crivello A, ColonnaRomano G, Candore G, Bonafe M, Cavallone L, Franceschi C, Caruso C (2002) Genderspecific association between 1082 IL10 promoter polymorphism and longevity. Genes Immun 3, 3033. (Pubitemid 38961103)
7. Shalit F, Sredni B, Brodie C, Kott E, Huberman M (1995) T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin Immunol Immunopathol 75, 246250.
8. Lombardi VR, Garcia M, Rey L, Cacabelos R (1999) Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol 97, 163171. (Pubitemid 29301426)
9. Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sancito L, Longhi R, Ferrante P (2007) Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging 28, 11631169. (Pubitemid 46810052)
10. Tan J, Town T,Abdullah L,WuY, PlaczekA, SmallB,Kroeger J, Crawford F, Richards D, Mullan M (2002) CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. J Neuroimmunol 132, 164172. (Pubitemid 35333339)
11. Rosenkranz D,Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L (2007) Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188, 117127. (Pubitemid 47095016)
12. Fehérvari Z, Sakaguchi S (2004) CD4+ Tregs and immune control. J Clin Invest 114, 12091217.
13. Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S (2000) Naturally anergic and suppressive CD25+CD4+ T cells as functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 12, 11451155. (Pubitemid 30618021)
14. Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic selftolerance and negative control of immune responses. Ann Rev Immunol 22, 531562. (Pubitemid 38680433)
15. Hori S, Takahashi T, Sakaguchi S (2003) Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 81, 331371. (Pubitemid 38009046)
16. Crispin JC, Martínez A, AlcocerVarela J (2003) Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21, 273276. (Pubitemid 37410115)
17. De Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, De Jager W, Pugayung G, Giannoni F, Rijkers G, Albani S, Kuis W, Prakken B (2004) CD4+CD25high regulatory T cells actively regulate inflammation in the joints of patients with the remitting formof juvenile idiopathic arthritis. J Immunol 172, 64356443. (Pubitemid 38621253)
18. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, LinSu K, Ten S, Sanz M, Exley M,Wilson B, Porcelli S,Maclaren N (2002) Multiple immunoregulatory defects in type1 diabetes. J Clin Invest 109, 131140. (Pubitemid 34052549)
19. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330336.
20. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rötzschke O, Falk K (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 12251232. (Pubitemid 47281420)
21. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204, 12571265. (Pubitemid 46919862)
22. Liu W, Putnam AL, XuYu Z, Szot G, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas De St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J ExpMed 203, 17011711. (Pubitemid 44036276)
23. Sansom DM, Walker LS (2006) The role of CD28 and cytotoxic Tlymphocyte antigen 4
24. [CTLA4] in regulatory Tcell biology. Immunol Rev 212, 131148.
25. Tang Q, Boden EK, Henriksen KJ, BourJordan H, Bi M, Bluestone JA (2004) Distinct roles of CTLA4 and TGFbeta in CD4+CD25+ regulatory T cell function. Eur J Immunol 34, 29963005.
26. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW (2006) Regulated compartmentalization of programmed cell death1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 176, 28082816. (Pubitemid 43306940)
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS ADRDA Work Group under the auspices ofDepartment ofHealth andHuman Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
28. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, DSMIII.R.
29. Folstein MF, Folstein SE, McHugh PR (1975) "Minimental state" A practical method for grading the cognitive state of patients for the clinicians. J Psychiat Res 12, 189198.
30. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for staging of dementia. Br J Psychiatry 140, 566572. (Pubitemid 12124384)
31. Petersen RC (2004)Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194. (Pubitemid 39222988)
32. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, De Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, Van Duijin C, Visser P, Peterson RC (2004) Mild cognitive impairment: beyond controversies, towards a consensus: Report of the International Working Group onMild Cognitive Impairment. J Intern Med 256, 240-246. (Pubitemid 39222993)
33. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, Kennes B, MüllerHermelink HK, Steinmann GG (1984) Admission criteria for immunogerontological studies in man: The SENIEUR protocol. Mech Ageing Dev 28, 4755. (Pubitemid 15222465)
34. Lyons AB (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243, 147154.
35. Saresella M, Marventano I, Guerini FR, Zanzottera M, Delbue S, Marchioni E, Macerati R, Longhi R, Ferrante P, Clerici M (2008) Myelin Basic ProteinSpecific T Lymphocytes Proliferation and Programmed Cell Death in Demyelinating Diseases. Clin Imm 129, 509517.
36. Gitter BD, Cox LM, Rydel LE, May PC (1995) Amyloid peptide potentiate cytokine secretion by interleukin 1 activated human astrocytoma cell. Proc Natl Acad Sci U S A 92, 1073810741.
37. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, EmmerlingM, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, PlataSalaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,WenkG, WyssCoray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383421. (Pubitemid 30349107)
38. Shoji M, Kanai M (2001) Cerebrospinal fluid Abeta40 and Abeta42: Natural course and clinical usefulness. J Alzheimers Dis 3, 313321. (Pubitemid 32577635)
39. Strazielle N, GhersiEgea JF, Ghiso J, Dehouck MP, Frangione B, Patlak C, Fenstermacher J, Gorevic P (2000) In vitro evidence that betaamyloid peptide 140 diffuses across the bloodbrain barrier and affects its permeability. J Neuropathol Exp Neurol 59, 2938. (Pubitemid 30069223)
40. CrawfordMP,Yan SX,Ortega SB,MehtaRS,HewittRE, Price DA, Stastny P, Douek DC, Koup RA, Racke MK, Karandikar NJ (2004) High prevalence of autoreactive, neuroantigenspecific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103, 42224231. (Pubitemid 38685367)
41. Venken K, Thewissen M, Hellings N, Somers V, Hensen K, Rummens JL, Stinissen P (2007) A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of autoantigen specific and polyclonal T cell responses. J Immunol Meth 322, 111. (Pubitemid 46560587)
42. Rojo LE, Fernández JA,Maccioni AA, Jimenez JM,Maccioni RB (2008) Neuroinflammation: Implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39, 116.
43. Marins Okura Y, Kohyama K, Park IK, Matsumoto Y (2008) Nonviral DNA vaccination augments microglial phagocytosis of betaamyloid deposits as a major clearance pathway in an Alzheimer disease mouse model. J Neuropathol Exp Neurol 67, 1063-1071.
44. Speciale L, Ruzzante S, Calabrese E, Saresella M, Taramelli D,Mariani C, Bava L, Longhi R, Ferrante P (2003) 140 Betaamyloid protein fragment modulates the expression of CD44 and CD71 on the astrocytoma cell line in the presence of IL1beta and TNFalpha. J Cell Physiol 196, 190195. (Pubitemid 36676457)
45. Lynch MA (2009) The multifaceted profile of activated microglia. Mol Neurobiol 40, 13956.
46. Jana M, Palencia CA, Pahan K (2008) Fibrillar amyloidbeta peptides activate microglia via TLR2: Implications for Alzheimer's disease. J Immunol 181, 72547262.
47. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK (2007) Chronic interleukin1beta expression in mouse brain leads to leukocyte infiltration and neutrophilindependent blood brain barrier permeability without overt neurodegeneration. J Neurosci 27, 9301-9309. (Pubitemid 47358197)
48. RezaiZadeh K, Gate D, Town T (2009) CNS infiltration of peripheral immune cells: DDay for neurodegenerative disease? J Neuroimmune Pharmacol 4, 462475.
49. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGFbetaSmad2/3 innate immune signaling mitigates Alzheimerlike pathology. Nat Med 14, 681687. (Pubitemid 351809551)
50. Hawkes CA,McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of betaamyloid in cerebral amyloid angiopathy. ProcNatlAcad SciUS A 106, 12611266.
51. Tan J, Town T, Suo Z, Wu Y, Song S, Kundtz A, Kroeger J, Humphrey J, Crawford F,MullanM(1999) Induction of CD40 on human endothelial cells by Alzheimer's betaamyloid peptides. Brain Res Bull 50, 143148. (Pubitemid 29467334)
52. Tan J, Town T, Mullan M (2002) CD40CD40L interaction in Alzheimer's disease. Curr Opin Pharmacol 2, 445451.
53. Town T, Nikolic V, Tan J (2005) The microglial activation continuum: from innate to adaptive responses. J Neuroinflammation 2, 24. (Pubitemid 41631819)
54. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E,Goldeck D, Fulop T (2009) Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 17, 91103.
55. Bryl E,Witkowski JM(2004) Decreased proliferative capability of CD4(+) cells of elderly people isassociated with faster loss of activationrelated antigens and accumulation of regulatory T cells. Exp Gerontol 39, 587595. (Pubitemid 38402085)
56. Trzonkowski P, Szmit E, Myśliwska J, Myśliwski A (2006) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humansimpact of immunosenescence. Clin Immunol 119, 307316.
57. Cortesini R, LeMaoult J, Ciubotariu R, SuciuFoca N (2001) CD8+CD28-T suppressor cells and the induction of antigenspecific, antigenpresenting cellmediated suppression of Th reactivity. Immunol Rev 182, 201206. (Pubitemid 33070219)
58. SuciuFoca N, Manavalan JS, Scotto L, KimSchulze S, Galluzzo S, Naiyer AJ, Fan J, Vlad G, Cortesini R (2005) Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: Review. Int Immunopharmacol 1, 711. (Pubitemid 39626678)
59. Ma SL, Tang NL, Lam LC, Chiu HF (2005) The association between promoter polymorphism of the interleukin10 gene and Alzheimer's disease. Neurobiol Aging 7, 10051010. (Pubitemid 40312663)